Dalane Kitzman to Adrenergic beta-Antagonists
This is a "connection" page, showing publications Dalane Kitzman has written about Adrenergic beta-Antagonists.
Connection Strength
0.622
-
Upadhya B, Kitzman DW. Beta-Blockers for Primary Therapy of Heart Failure With Preserved Ejection Fraction: An Idea Whose Time Has Gone? J Card Fail. 2020 03; 26(3):283-284.
Score: 0.174
-
Patel K, Fonarow GC, Ekundayo OJ, Aban IB, Kilgore ML, Love TE, Kitzman DW, Gheorghiade M, Allman RM, Ahmed A. Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes. Int J Cardiol. 2014 May 15; 173(3):393-401.
Score: 0.116
-
Dobre D, Zannad F, Keteyian SJ, Stevens SR, Rossignol P, Kitzman DW, Landzberg J, Howlett J, Kraus WE, Ellis SJ. Association between resting heart rate, chronotropic index, and long-term outcomes in patients with heart failure receiving ß-blocker therapy: data from the HF-ACTION trial. Eur Heart J. 2013 Aug; 34(29):2271-80.
Score: 0.107
-
Fiuzat M, Wojdyla D, Kitzman D, Fleg J, Keteyian SJ, Kraus WE, Piña IL, Whellan D, O'Connor CM. Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. J Am Coll Cardiol. 2012 Jul 17; 60(3):208-15.
Score: 0.102
-
Keteyian SJ, Kitzman D, Zannad F, Landzberg J, Arnold JM, Brubaker P, Brawner CA, Bensimhon D, Hellkamp AS, Ewald G. Predicting maximal HR in heart failure patients on ß-blockade therapy. Med Sci Sports Exerc. 2012 Mar; 44(3):371-6.
Score: 0.101
-
Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011 Apr; 32(7):820-8.
Score: 0.023